{"type":"trials","record":{"id":28326,"source_id":"clinicaltrials-gov","external_id":"NCT06319872","title":"The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration","brief_summary":"Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.","overall_status":"Recruiting","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"University of Rochester","enrollment":15,"countries":["United States"],"start_date":"2025-05-19","completion_date":"2029-05-19","last_update_date":"2026-09-16","source_url":"https://clinicaltrials.gov/study/NCT06319872","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"University of Rochester","interventions":["Oral disulfiram"],"registry_source":"ClinicalTrials.gov","outcome_measures":["mean change in Best Corrected Visual Acuity (BCVA) score assessed by ETDRS — baseline to day 180","mean change in total contrast sensitivity score using Pelli-Robson charts — baseline to day 180","mean change in light-adapted microperimetry sensitivity assessed using standard MAIA microperimetry equipment — baselin…","mean change in outer retinal thickness assessed using Spectral Domain Optical Coherence Tomography (SD-OCT) — baseline…","mean change in fundus autofluorescence (FAF) — baseline to day 180","number of participants with retinal anatomy changes assessed using fundus photos — baseline to day 180","mean change in visual field perimetry using full-field stimulus test — baseline to day 180","mean change in isopter constriction using Goldmann visual field — baseline to day 180","mean change in size of scotomas using Goldmann visual field — baseline to day 180","mean change in cone and rod latency assessed using Full field electroretinogram (ffERG) — baseline to day 180","mean change in cone and rod amplitude assessed using Full field electroretinogram (ffERG) — baseline to day 180","mean change in cone and rod latency assessed using multifocal electroretinogram (mfERG) — baseline to day 180","mean change in cone and rod amplitude assessed using multifocal electroretinogram (mfERG) — baseline to day 180","mean change in National Eye Institute-Visual Functioning Questionnaire 25 composite score. — baseline to day 180"],"design_description":"NA · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Alcohol Use Disorder","Retinal Dystrophies","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Oral disulfiram"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06319872","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-05-19 to 2029-05-19","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.797Z","intervention":["Oral disulfiram"],"participants":15,"study_design":"NA · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["mean change in Best Corrected Visual Acuity (BCVA) score assessed by ETDRS — baseline to day 180","mean change in total contrast sensitivity score using Pelli-Robson charts — baseline to day 180","mean change in light-adapted microperimetry sensitivity assessed using standard MAIA microperimetry equipment — baselin…","mean change in outer retinal thickness assessed using Spectral Domain Optical Coherence Tomography (SD-OCT) — baseline…","mean change in fundus autofluorescence (FAF) — baseline to day 180","number of participants with retinal anatomy changes assessed using fundus photos — baseline to day 180","mean change in visual field perimetry using full-field stimulus test — baseline to day 180","mean change in isopter constriction using Goldmann visual field — baseline to day 180","mean change in size of scotomas using Goldmann visual field — baseline to day 180","mean change in cone and rod latency assessed using Full field electroretinogram (ffERG) — baseline to day 180","mean change in cone and rod amplitude assessed using Full field electroretinogram (ffERG) — baseline to day 180","mean change in cone and rod latency assessed using multifocal electroretinogram (mfERG) — baseline to day 180","mean change in cone and rod amplitude assessed using multifocal electroretinogram (mfERG) — baseline to day 180","mean change in National Eye Institute-Visual Functioning Questionnaire 25 composite score. — baseline to day 180"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28326","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}